Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity
| Autor: | Susan L. Hogan, Cindy L. O'Bryant, Yichun Hu, Blessy George, Madeleine Gomez, Xia Wen, Daniel W. Bowles, Melanie S. Joy, Lauren M. Aleksunes, Nickie Mercke |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Urinary system Urology Renal function Antineoplastic Agents Urine Kidney Function Tests Calbindin Article Nephrotoxicity 03 medical and health sciences chemistry.chemical_compound Neoplasms medicine Humans Pharmacology (medical) Prospective Studies Aged Aged 80 and over Pharmacology Cisplatin Creatinine Trefoil factor 3 business.industry Acute Kidney Injury Middle Aged 030104 developmental biology chemistry Female business Biomarkers medicine.drug |
| Zdroj: | Clinical Pharmacology & Therapeutics. 101:510-518 |
| ISSN: | 0009-9236 |
| Popis: | The success of cisplatin-containing regimens to treat solid tumors is limited, in part, by nephrotoxicity. In rodents, several urinary proteins have emerged that are sensitive indicators of cisplatin-induced kidney injury. We sought to characterize time-dependent changes in the urinary concentrations of 12 proteins, including kidney injury molecule-1 (KIM-1), calbindin, beta 2-microglobulin (β2M), and trefoil factor 3 (TFF3) after cisplatin therapy. Urine was collected at baseline, 3 days (range, 2-5 days), and 10 days (range, 9-11 days) from 57 patients with solid tumors receiving outpatient cisplatin therapy (≥25 mg/m2 ). Serum creatinine was largely unchanged after cisplatin infusion. However, compared with baseline values, several novel biomarkers were significantly increased in the urine, including β2M, which was threefold higher by day 3 (P < 0.0001). Urinary KIM-1 and TFF3 were elevated twofold by day 10 (P = 0.002 and P = 0.002, respectively), whereas calbindin levels were increased eightfold (P < 0.0001). We report novel time-dependent changes in the urinary excretion of noninvasive markers of subclinical kidney injury after cisplatin treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text